Compare EXPE & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPE | IQV |
|---|---|---|
| Founded | 1996 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Transportation Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 28.6B |
| IPO Year | 2005 | 2013 |
| Metric | EXPE | IQV |
|---|---|---|
| Price | $214.22 | $167.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 16 |
| Target Price | ★ $275.89 | $227.13 |
| AVG Volume (30 Days) | 1.6M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 9.61 | 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | ★ $14,733,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $10.35 | $6.77 |
| Revenue Next Year | $6.93 | $5.89 |
| P/E Ratio | ★ N/A | $104.62 |
| Revenue Growth | 7.61 | ★ 41.60 |
| 52 Week Low | $161.02 | $137.33 |
| 52 Week High | $303.80 | $247.05 |
| Indicator | EXPE | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 46.35 |
| Support Level | $211.23 | $159.08 |
| Resistance Level | $216.60 | $172.80 |
| Average True Range (ATR) | 9.15 | 7.14 |
| MACD | -2.10 | -0.24 |
| Stochastic Oscillator | 15.43 | 44.08 |
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.